Key clinical point: Incidence of graft vs. host disease was significantly lower in patients undergoing matched sibling donor stem cell transplants who received low-dose rabbit antitymoctye globulin (rATG).
Major finding: The 2-year cumulative incidences of chronic GVHD (cGVHD) were 35.4% and 60.4%, respectively, for patients in the rATG and non-rATG groups ( P=0.039).
Study details: The data come from a retrospective study of 79 patients aged 16 years and older with hematologic malignancies who were treated with matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT); all received standard prophylaxis and 38 received 5 mg/kg of rATG in addition.
Disclosures: The study was supported in part by the Scientific Research Seed Fund of Peking University First Hospital. The researchers had no financial conflicts to disclose.
Source: Song ZY et al. Cancer Manag Res. 2020 Nov 30. doi: 10.2147/CMAR.S283855.